Please note, this OEL/ADE monograph also applies to Dihydroartemisinin (CAS RN 71939-50- 9). Artemisinin is a sesquiterpene lactone obtained from sweet wormwood (Artemisia annua) which is used as an antimalarial for the treatment of multi-drug resistant strains of falciparum malaria. Dihydroartemisinin (also known as artenimol and DHA) is an artemisinin derivative and antimalarial agent used in the treatment of uncomplicated Plasmodium falciparum infections. Artemisinin combination therapy is highly effective against malaria and strongly recommended by the World Health Organization (WHO). It is the active metabolite of all artemisinin compounds (artemisinin, artesunate, and artemether among others).
Affygility Solutions has an occupational exposure limit (OEL) and control band assignment for this active pharmaceutical ingredient (API). This monograph also contains the acceptable daily exposure (ADE) value.
OEL Fastrac monographs are a cost-effective and convenient way to meet the requirements for PDEs (ADEs) contained in the EMA Guideline on setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities (EMA/CHMP/CVMP/SWP/169430/2012), as well as PIC/S and ANVISA requirements, and to obtain the following information:
To order an OEL/ADE monograph for Artemisinin, just click the ADD TO CART button.
If you're wondering about HBEL, we have something for you.
Not the compound you were looking for? You can search the OEL Fastrac catalog to find more available compounds.
Affygility Solutions’ OEL Fastrac service is an user-friendly system that enables us to make confident decisions and focus on moving the compound safely through our facility. We can quickly access the database to determine if a new drug is within the OEL Fastrac library, and if so, immediately download a detailed OEL banding report. The OEL Fastrac system has been a helpful tool in our overall EH&S program.